New drug cocktail tested for Tough-to-Treat leukemia in older patients
NCT ID NCT04964505
Summary
This early-stage study tested the safety of combining three drugs—uproleselan, azacitidine, and venetoclax—for older adults or those too frail for standard intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The goal was to see if this combination could kill more cancer cells while being tolerable for this vulnerable patient group. The study was small and focused primarily on finding the safest dose and understanding side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.